The MET proto-oncogene encoded receptor tyrosine kinase MET and AXL receptor tyrosine kinase (AXL) are independently operating receptor tyrosine kinases (RTKs) that are functionally associated with aggressive and invasive cancer cell growth. However, how MET and AXL regulate the migratory properties of cancer cells remains largely unclear. We report here that addition of hepatocyte growth factor (HGF), the natural ligand of MET, to serum-starved human glioblastoma cells induces the rapid activation of both MET and AXL and formation of highly polarized MET-AXL clusters on the plasma membrane. HGF also promoted the formation of the MET and AXL protein complexes and phosphorylation of AXL, independently of the AXL's ligand, growth arrest-specific 6 (GAS6). The HGF-induced MET-AXL complex stimulated the rapid and dynamic cytoskeleton reorganization by activating the small GTPase RAC1, a process requiring both MET and AXL kinase activities. We further found that HGF also promotes the recruitment of ELMO2 and DOCK180, a bipartite guanine nucleotide exchange factor for RAC1, to the MET-AXL complex and thereby stimulates the RAC1-dependent cytoskeleton reorganization. We also demonstrated that the MET-AXL-ELMO2-DOCK180 complex is critical for HGF-induced cell migration and invasion in glioblastoma or other cancer cells. Our findings uncover a critical HGF-dependent signaling pathway that involves the assembly of a large protein complex consisting of MET, AXL, ELMO2, and DOCK180 on the plasma membrane, leading to RAC1-dependent cell migration and invasion in various cancer cells. __________________________________The MET oncogene was originally identified as the oncogenic TPR-MET fusion gene due to a chromosomal translocation fusion event in an osteosarcoma cell line (1,2). The TPR-MET fusion protein exhibits a constitutively active MET tyrosine kinase (RTK) that is normally expressed in cells of epithelial origins during embryonic development for mitogenesis and morphogenesis of various tissues (1,2). In embryogenesis or wound healing process in adult tissues, activation of the MET RTK by its cognate ligand, hepatocyte growth factor (HGF, also called scatter factor), initiates a morphogenic program of "invasive growth" that promotes disruption and remodeling of intercellular contacts, accompanied by cell proliferation, cell migration and invasion (1,2). The MET-dependent invasive growth signals are also present in many highly aggressive cancer cells. The abnormalities of MET in human malignancies are frequent and widely observed (1,2). In glioblastoma multiforme (GBM), a highly aggressive brain tumor, the level of MET is often aberrantly up-regulated (3). Notably, abnormal activation of MET is responsible for resistance to targeted therapies against the vascular endothelial growth factor receptor (VEGFR) in GBM and inhibitors of the epidermal growth factor receptor (EGFR) in lung cancers (4-6). Although it is well known that upon the binding to HGF, MET is phosphorylated and activated on the plasma membrane, ...